Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Reeves

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 28, 2026
Patient and public involvement and engagement in clinical trials at scale: Analysis of the first 3250 responses on the POrtal for Patient and Public Engagement in Dementia (POPPED)Hongyi Qin, Linda Pointon, James Carpenter, et al.
The Journal of Clinical Psychiatry|September 1, 2017
A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's DiseaseSuzanne Reeves, Julie Bertrand, Emma McLachlan, et al.
The Lancet. Psychiatry|March 16, 2019
Clinical and cost-effectiveness of the Managing Agitation and Raising Quality of Life (MARQUE) intervention for agitation in people with dementia in care homes: a single-blind, cluster-randomised controlled trialGill Livingston, Julie Barber, Louise Marston, et al.
Psychological Medicine|March 24, 2025
Minimal clinically important differences for treatment of hallucinations in Parkinson's disease and dementia with Lewy bodiesSuzanne Reeves, Josef Mahdi, Matthew Appleby, et al.
Ageing Research Reviews|March 2, 2025
Systematic review of clinical effectiveness of interventions for treatment resistant late-life depressionBeatriz Pozuelo Moyano, Denise Gomez Bautista, Karla Jocelyn Porras Ibarra, et al.
International Journal of Geriatric Psychiatry|March 1, 2014
Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F]fallypride positron emission tomographyChloe Clark-Papasavas, Joel T Dunn, Suki Greaves, et al.
JAMA Neurology|November 19, 2019
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical TrialRobert Howard, Olga Zubko, Rosie Bradley, et al.
The Lancet. Psychiatry|June 9, 2018
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trialRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Health Technology Assessment (Winchester, England)|December 4, 2018
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCTRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 26, 2026
Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's diseaseSabahat Iqbal, Cristina Bonet Olivares, Laura Rizzo, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 28, 2026
Patient and public involvement and engagement in clinical trials at scale: Analysis of the first 3250 responses on the POrtal for Patient and Public Engagement in Dementia (POPPED)Hongyi Qin, Linda Pointon, James Carpenter, et al.
The Journal of Clinical Psychiatry|September 1, 2017
A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's DiseaseSuzanne Reeves, Julie Bertrand, Emma McLachlan, et al.
The Lancet. Psychiatry|March 16, 2019
Clinical and cost-effectiveness of the Managing Agitation and Raising Quality of Life (MARQUE) intervention for agitation in people with dementia in care homes: a single-blind, cluster-randomised controlled trialGill Livingston, Julie Barber, Louise Marston, et al.
Psychological Medicine|March 24, 2025
Minimal clinically important differences for treatment of hallucinations in Parkinson's disease and dementia with Lewy bodiesSuzanne Reeves, Josef Mahdi, Matthew Appleby, et al.
Ageing Research Reviews|March 2, 2025
Systematic review of clinical effectiveness of interventions for treatment resistant late-life depressionBeatriz Pozuelo Moyano, Denise Gomez Bautista, Karla Jocelyn Porras Ibarra, et al.
International Journal of Geriatric Psychiatry|March 1, 2014
Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F]fallypride positron emission tomographyChloe Clark-Papasavas, Joel T Dunn, Suki Greaves, et al.
JAMA Neurology|November 19, 2019
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical TrialRobert Howard, Olga Zubko, Rosie Bradley, et al.
The Lancet. Psychiatry|June 9, 2018
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trialRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Health Technology Assessment (Winchester, England)|December 4, 2018
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCTRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 26, 2026
Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's diseaseSabahat Iqbal, Cristina Bonet Olivares, Laura Rizzo, et al.
Pageof 5